{"groups":[{"description":"IMC-A12 + Multi-agent intensive chemotherapy regimen.","id":"FG000","title":"IMC-A12"},{"description":"Add temozolomide to vincristine/irinotecan cycles.","id":"FG001","title":"Temozolomide"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"4"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"19"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"5"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"5"}],"type":"Ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"4"}],"type":"Refusal of further protocol therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"No treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"100"},{"groupId":"FG001","numSubjects":"75"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"55"},{"groupId":"FG001","numSubjects":"37"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"38"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"The number of participants started is 175. Eight patients were declared ineligible by the study chair, and one patient didn't receive treatment."}